Evidence map›Paper›PMID 25092310›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2014

Multimonth controlled small molecule release from biodegradable thin films.

Bryan B Hsu, Myoung-Hwan Park, Samantha R Hagerman, Paula T Hammond

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bryan B HsuDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139;Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139;Institute for Soldier Nanotechnologies, Cambridge, MA 02139; and.
Myoung-Hwan ParkDepartment of Chemistry, Sahmyook University, Seoul 139-742, Korea; and.
Samantha R HagermanDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.
Paula T HammondKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139;Institute for Soldier Nanotechnologies, Cambridge, MA 02139; andDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139 hammond@mit.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long-term, localized delivery of small molecules from a biodegradable thin film is challenging owing to their low molecular weight and poor charge density. Accomplishing highly extended controlled release can facilitate high therapeutic levels in specific regions of the body while significantly reducing the toxicity to vital organs typically caused by systemic administration and decreasing the need for medical intervention because of its long-lasting release. Also important is the ability to achieve high drug loadings in thin film coatings to allow incorporation of significant drug amounts on implant surfaces. Here we report a sustained release formulation for small molecules based on a soluble charged polymer-drug conjugate that is immobilized into nanoscale, conformal, layer-by-layer assembled films applicable to a variety of substrate surfaces. We measured a highly predictable sustained drug release from a polymer thin film coating of 0.5-2.7 μm that continued for more than 14 mo with physiologically relevant drug concentrations, providing an important drug delivery advance. We demonstrated this effect with a potent small molecule nonsteroidal anti-inflammatory drug, diclofenac, because this drug can be used to address chronic pain, osteoarthritis, and a range of other critical medical issues.

Indexed as

Biocompatible MaterialsDrug Delivery SystemsAnti-Inflammatory Agents, Non-SteroidalDiclofenacPolymersAnti-Inflammatory Agents, Non-SteroidalBiocompatible MaterialsDiclofenacPolymersNSAIDpolyelectrolyte multilayerspolymer prodrug

Identifiers

PMID25092310
PMCPMC4143022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.